Heron Therapeutics, Inc. — Q1 2021 Form 10-Q Summary
Business context and reporting period
Heron Therapeutics is a commercial-stage biotechnology company developing and commercializing treatments for oncology and acute-care patients. The filing covers the three months ended March 31, 2021, compared with the three months ended March 31, 2020. Commercial products were CINVANTI and SUSTOL in the United States and ZYNRELEF in Europe. The company also had product candidates HTX-011, HTX-034 and HTX-019 in development.
Financial performance and liquidity
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Net product sales | $20.0 million | $25.4 million | Down 21.2% |
| Cost of product sales | $9.2 million | $10.6 million | Down 13.3% |
| Gross profit | Approximately $10.8 million | Approximately $14.8 million | Down 27.0% |
| Gross margin | Approximately 54.0% | Approximately 58.2% | Down approximately 4.2 percentage points |
| Research and development | $38.1 million | $36.9 million | Up 3.3% |
| General and administrative | $9.6 million | $10.4 million | Down 8.1% |
| Sales and marketing | $15.2 million | $20.2 million | Down 24.6% |
| Loss from operations | $(52.1) million | $(52.7) million | Slightly improved |
| Net loss | $(52.6) million | $(51.6) million | Loss increased 2.0% |
| Net loss per share | $(0.58) | $(0.57) | Higher loss per share |
| Net cash used in operating activities | $(41.9) million | $(32.9) million | Cash use increased |
CINVANTI revenue was $18.5 million, down from $25.2 million, while SUSTOL revenue increased to $1.5 million from $0.2 million after the company reinstated SUSTOL promotion and contracting. The filing attributes lower CINVANTI sales primarily to COVID-19-related reductions in cancer screening and treatment starts and the lingering impact of generic competition.
Gross margin declined as revenue decreased faster than cost of product sales. Operating margin was approximately negative 260%, compared with approximately negative 208% in the prior-year quarter; net margin was approximately negative 263%, compared with approximately negative 203%.
Cash, cash equivalents and short-term investments totaled $166.5 million at March 31, 2021, compared with $208.5 million at December 31, 2020. Cash and cash equivalents alone were $59.7 million. The company reported $4.3 million of net cash used in investing activities and $0.9 million of net cash provided by financing activities. Management stated that existing liquidity should fund anticipated cash requirements for at least one year from the filing date.
Total liabilities were $114.7 million and stockholders’ equity was $196.2 million at March 31, 2021. Convertible notes payable to related parties had a carrying value of $7.6 million and a principal amount of approximately $7.7 million. The notes matured on May 2, 2021, and holders subsequently converted the outstanding principal and accrued interest into 9.8 million common shares in May 2021, eliminating the remaining obligations.
Material changes versus the prior comparable period
- Revenue declined by $5.4 million, driven by a $6.7 million decrease in CINVANTI sales, partially offset by a $1.3 million increase in SUSTOL sales.
- Research and development expense increased by $1.2 million, primarily because of increased PONV and HTX-034 development spending.
- Sales and marketing expense decreased by $5.0 million, principally because of lower HTX-011 launch-preparation costs.
- Operating cash use increased by $9.0 million, primarily due to working-capital changes.
- Cash and short-term investments declined by $42.0 million from year-end 2020.
- Stock-based compensation remained significant at $11.5 million, compared with $12.0 million in Q1 2020. Unrecognized future stock-based compensation was $104.4 million at March 31, 2021.
Guidance, outlook, commentary and risks
- Management expected oncology-care product sales to grow in 2021 and beyond, stating that the most significant impact of generic arbitrage was over. No specific revenue or earnings guidance was provided.
- ZYNRELEF had European marketing authorization in 31 countries, and the company anticipated making it available to European patients during 2022 while building manufacturing capacity.
- HTX-011 was resubmitted to the FDA after a June 2020 Complete Response Letter. The FDA identified four non-clinical issues but no clinical safety, efficacy or chemistry, manufacturing and controls issues. The PDUFA goal date was May 12, 2021.
- The expanded Phase 2 portion of the HTX-034 study began in the first quarter of 2021. An NDA for HTX-019 for postoperative nausea and vomiting was planned for late 2021.
- The company continued to evaluate CINVANTI in a Phase 2 study for early hospitalized COVID-19 patients; the program remained early-stage and required additional testing and funding.
- Major risks include continued COVID-19 effects on cancer treatment and elective surgery volumes, generic competition, product pricing and reimbursement pressure, regulatory delays or non-approval, manufacturing and supply-chain dependence, clinical-trial uncertainty, intellectual-property challenges and the need for additional capital if operating cash requirements exceed current resources.
- Product sales and accounts receivable were highly concentrated among three customers, representing 99.1% of Q1 2021 net product sales and 99.4% of accounts receivable at March 31, 2021.
- The company reported no material legal proceedings, no off-balance-sheet arrangements and effective disclosure controls as of March 31, 2021.
Important facts for investors to verify
- Whether CINVANTI sales recover as COVID-19-related treatment disruptions ease and generic competition stabilizes.
- The FDA’s action on HTX-011 following the May 12, 2021 PDUFA date and the timing and economics of any U.S. launch.
- The commercial launch timing, manufacturing readiness and reimbursement outlook for ZYNRELEF in Europe.
- Whether the company can reduce quarterly operating cash burn while advancing HTX-034, HTX-019 and the COVID-19 program.
- The effect of the May 2021 conversion of the convertible notes on share count and potential dilution.
- Customer concentration, product-return and rebate accrual estimates, inventory levels and potential inventory write-downs.
- Whether the stated liquidity runway remains adequate if product launches, regulatory reviews or clinical programs are delayed.